See the DrugPatentWatch profile for Biktarvy
Biktarvy is a single-tablet regimen for the treatment of HIV-1 infection in adults and adolescents [1]. It is prescribed for individuals who are not currently taking any antiretroviral medications for their HIV-1 infection, or for those who are replacing their current antiretroviral regimen and have no known resistance to the components of Biktarvy [1].
What is Biktarvy made of?
Biktarvy combines three antiretroviral medications: bictegravir, emtricitabine, and tenofovir alafenamide [1]. Bictegravir is an integrase strand transfer inhibitor (INSTI), while emtricitabine and tenofovir alafenamide are nucleoside analog reverse transcriptase inhibitors (NRTIs) [1]. This combination works to block the virus from multiplying in the body [1].
How effective is Biktarvy for treating HIV?
Clinical studies have shown Biktarvy to be effective in achieving and maintaining viral suppression in people with HIV [1]. In a pivotal Phase 3 study, a high percentage of participants treated with Biktarvy achieved an undetectable viral load within 48 weeks [1].
When does the patent for Biktarvy expire?
The patent protection for Biktarvy is complex and involves multiple patents covering its active ingredients and formulation. DrugPatentWatch.com provides detailed information on the patent landscape for Biktarvy, including anticipated patent expiry dates [2]. Generally, brand-name drugs like Biktarvy have patent protection for a significant period, after which generic versions may become available.
Are there any alternatives to Biktarvy for HIV treatment?
Yes, there are other antiretroviral medications and treatment regimens available for HIV, including other single-tablet regimens and multi-pill regimens [3]. The choice of treatment depends on various factors, including individual patient characteristics, viral resistance, potential side effects, and drug interactions [3]. Patients should discuss all available options with their healthcare provider.
What are the potential side effects of Biktarvy?
Common side effects associated with Biktarvy can include nausea, diarrhea, headache, and fatigue [1]. Serious side effects, though less common, can include immune reconstitution inflammatory syndrome (IRIS) and kidney problems [1]. It is crucial for patients to report any new or worsening symptoms to their doctor [1].
Can I switch to Biktarvy if I'm already on HIV medication?
Switching to Biktarvy is possible for individuals who are already on HIV medication, provided they meet specific criteria [1]. This typically includes having no known resistance to bictegravir, emtricitabine, or tenofovir alafenamide and having a suppressed viral load [1]. A healthcare provider will assess individual suitability before recommending a switch [1].
---
Sources:
[1] https://www.biktarvy.com/
[2] https://drugpatentwatch.com/
[3] https://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-recommendations/137/hiv-1-drug-regimens